Showing results (61-70 of 419) with videos related to
Sort By:
Pageof 42
Biomedicine Hub|August 11, 2020
β-Blocker Doses and Heart Rate in Patients with Heart Failure: Results from the National Norwegian Heart Failure RegistryTorfinn Eriksen-Volnes, Arne Westheim, Lars Gullestad, et al.Journal of Cardiopulmonary Rehabilitation|April 2, 2003
Physical activity patterns and exercise performance in cardiac transplant recipientsJonathan Myers, Lars Gullestad, Daniel Bellin, et al.Heart Failure Reviews|March 9, 2018
The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventionsAnne Pernille Ofstad, Dan Atar, Lars Gullestad, et al.Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|October 23, 2018
Myocardial fibrosisTorvald Espeland, Ida Gjervold Lunde, Brage H Amundsen, et al.Scandinavian Journal of Public Health|February 10, 2017
Reproducibility of an extensive self-report questionnaire used in secondary coronary preventionKari Peersen, John Munkhaugen, Lars Gullestad, et al.Scientific Reports|October 30, 2020
Distinct patterns of soluble leukocyte activation markers are associated with etiology and outcomes in precapillary pulmonary hypertensionTove Lekva, Lars Gullestad, Kaspar Broch, et al.Clinical Transplantation|November 22, 2015
Peak oxygen uptake and self-reported physical health are strong predictors of long-term survival after heart transplantationMarianne Yardley, Odd E Havik, Ingelin Grov, et al.Cardiology|November 20, 2013
A pharmacokinetic and pharmacodynamic comparison of immediate-release metoprolol and extended-release metoprolol CR/XL in patients with suspected acute myocardial infarction: a randomized, open-label studyBjörn W Karlson, Mikael Dellborg, Lars Gullestad, et al.The American Journal of Cardiology|March 5, 2004
Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failureAina Hognestad, Kenneth Dickstein, Eivind Myhre, et al.American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|May 17, 2007
Potential mechanisms of benefit with thalidomide in chronic heart failurePål Aukrust, Arne Yndestad, Jan Kristian Damås, et al.Pageof 42